LexisNexis® 40 UNDER 40 2022 律商聯訊「40位40歲以下精英」榜單

Edward Tung 董梓光

Head of Legal and Compliance

ORI Capital 新元資本

LexisNexis® 40 UNDER 40 2022 律商聯訊「40位40歲以下精英」榜單

Edward is the Head of Legal and Compliance of ORI Capital. ORI invests in innovative companies in the healthcare industry globally. Edward’s work at ORI embraces legal work at all parts of ORI’s operations, including fund formation, investment, portfolio management and disposal of investments. Before Edward’s legal career, he was a scientist at the Faculty of Medicine at the University of Hong Kong, where he obtained his Ph.D. With his background in both life sciences and law, he is also the head of the risk management committee which handles scientific, legal and financial risks of potential investments.

Notable transactions handled by Edward include the launch of ORI Healthcare Fund II and the sale of Kymab Limited by ORI Healthcare Fund to Sanofi at up to US$1.5 billion total consideration. ORI Healthcare Fund II focuses on investing in innovative companies in the therapeutics, drug delivery and diagnostics areas that address major diseases or diseases with high mortality rates. Kymab’s products target immune disorders, cancer and haematological diseases, potentially benefiting millions of people worldwide.

Edward is also a founding director of Biomedical Impact Association, a non-profit organisation founded in 2022 to promote patient benefits, facilitate resource exchanges and assist biotechnological developments in Hong Kong.

Edward is widely recognised in Asia, China and Hong Kong with awards and nominations at Asian Legal Business Hong Kong Law Awards, Asia Legal Awards and China Law & Practice Awards.

董梓光(Edward Tung) 是 ORI Capital 的法務合規主管。 ORI 投資全球醫療行業的創新公司。 Edward 在 ORI 的法律工作涵蓋運營各個環節,包括基金設立、投資、投資管理和退出。在從事法律工作之前,他在香港大學醫學院從事醫學研究並修得博士學位。憑藉他在生命科學和法律方面的背景,他亦是ORI風險管理委員會的主席,該委員會負責考慮潛在投資的科學、法律和財務風險。

Edward 處理的重要交易包括發行 ORI Healthcare Fund II 以及 ORI Healthcare Fund 以總對價高達 15 億美元出售 Kymab Limited 與賽諾菲。 ORI Healthcare Fund II 專注於投資應對重大疾病或高死亡率疾病的治療、藥物輸送和診斷領域的創新公司。 Kymab 的產品針對免疫疾病、癌症和血液疾病,全球潛在受益病人高達數百萬。

Edward 亦是 Biomedical Impact Association 的創始董事,該非牟利組織成立於2022年,旨在促進患者福利,促進資源交流和協助香港的生物技術發展。

Edward 在亞洲、中國和香港獲得廣泛認可,在ALB香港法律大獎(Asian Legal Business Hong Kong Law Awards)、亞洲法律大獎(Asia Legal Awards)和中國法律商務大獎(China Law & Practice Awards)等獲得多個獎項和提名。